Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Merck Completes Tender Offer to Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares...

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Civitas, Entegra, and Immune Design on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Civitas Solutions, Inc., Entegra Financial Corp., and Immune Design Corp. Additional...

CIVI : 17.76 (+0.11%)
ENFC : 23.85 (unch)
IMDZ : 5.85 (unch)
IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Rigrodsky & Long, P.A.:

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

ELLI : 98.99 (unch)
MXWL : 4.43 (-0.67%)
CASM : 2.45 (+0.41%)
IMDZ : 5.85 (unch)
STI : 62.73 (-1.20%)
ULTI : 330.48 (+0.02%)
LABL : 49.85 (-0.02%)
Merck Begins Tender Offer to Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of...

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

ELLI : 98.99 (unch)
MXWL : 4.43 (-0.67%)
CASM : 2.45 (+0.41%)
IMDZ : 5.85 (unch)
STI : 62.73 (-1.20%)
ULTI : 330.48 (+0.02%)
LABL : 49.85 (-0.02%)
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
ABBV : 78.88 (+1.69%)
RHHBY : 32.8800 (+0.58%)
Merck to Buy Immunotherapy Developer Immune Design for $300M

Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

MRK : 73.32 (+0.18%)
LLY : 115.25 (+0.04%)
IMDZ : 5.85 (unch)
BMY : 45.25 (-0.59%)
Thinking about buying stock in Apple, Canopy Growth Corp, Immune Design, Roku Inc or Zosano Pharma?

InvestorsObserver issues critical PriceWatch Alerts for AAPL, CGC, IMDZ, ROKU, and ZSAN.

ROKU : 56.48 (-0.35%)
AAPL : 203.79 (-0.03%)
IMDZ : 5.85 (unch)
ZSAN : 3.56 (+4.71%)
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

NVO : 48.30 (-0.19%)
MRK : 73.32 (+0.18%)
LLY : 115.25 (+0.04%)
IMDZ : 5.85 (unch)
ABBV : 78.88 (+1.69%)
RHHBY : 32.8800 (+0.58%)
PFE : 39.29 (-0.23%)
IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Rigrodsky & Long, P.A.:

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp.

Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by...

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Immune Design Corp.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Immune Design Corp. ("IMDZ" or the "Company") (NASDAQ: IMDZ) in connection with...

IMDZ : 5.85 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
Merck to Acquire Immune Design

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which...

MRK : 73.32 (+0.18%)
IMDZ : 5.85 (unch)
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

PTGX : 10.48 (+0.10%)
LGND : 124.90 (+2.28%)
IMDZ : 5.85 (unch)
SNY : 41.36 (+0.12%)
Immune Design: 1Q Earnings Snapshot

SEATTLE (AP) _ Immune Design Corp. (IMDZ) on Wednesday reported a loss of $13.3 million in its first quarter.

IMDZ : 5.85 (unch)
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update

-- The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3

IMDZ : 5.85 (unch)
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .

CELG : 93.60 (-0.17%)
IMDZ : 5.85 (unch)
GILD : 63.19 (+0.38%)
PFE : 39.29 (-0.23%)
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update

Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S....

IMDZ : 5.85 (unch)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ unch
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar